Samsara Vision

10/22/2025

Samsara Vision is proud to sponsor and attend OSN New York & Retina. This distinguished event, in the heart of Times Square, unites ophthalmologists and retina specialists to share the latest updates, showcase innovations and foster connections.

Will we see you there? Comment below so Don can keep his eye out for you.

10/21/2025

Scenes from AAO this past weekend. AAO2025, representing Samsara Vision.

The team had a busy few days, engaging with leaders across the industry. We were happy to receive positive feedback and support for the SING IMT®️.

Next up: OSN New York & Retina on November 7th. Let us know if we'll see you there.

10/16/2025

PRESS RELEASE: Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision. Samsara Vision Attending American Academy of Ophthalmology (AAO) 2025.

Four new clinical sites recently opened across the United States and Puerto Rico,
thereby increasing access to eligible study candidates, aged 65 and older, living with late-stage AMD.
There are now thirteen Concerto clinical trials sites across the United States and Puerto Rico.

The sites recently joining the study include:

🌎Cincinnati Eye Institute (Cincinnati, OH) – Principal Investigator: Michael Snyder, MD
🌎Georgia Eye Partners (Woodstock, GA) – Principal Investigator: Evan Schoenberg, MD
🌎North Valley Eye Care (Chico, CA) – Principal Investigator: Terrence Spencer, MD
🌎Instituto de Ojos (Carolina, PR) – Principal Investigator: Miguel Santiago, MD

The press release also announced our attendance of the American Academy of Ophthalmology annual meeting (AAO 2025 –booth #1803) to directly connect with providers about Concerto and offer insights about the SING IMT®️ in CE referenced countries where it is already approved and available for use.

Read more here: https://www.businesswire.com/news/home/20251016658910/en/Samsara-Vision-Expands-U.S.-and-Puerto-Rico-Clinical-Study-Sites-for-the-Smaller-Incision-New-Generation-Implantable-Miniature-Telescope-SING-IMT

10/15/2025

10/14/2025

”We’re excited to advance the PERSPECTIVE clinical trial to generate meaningful data to inform a possible label expansion so that we can offer our sight-enhancing device to many more patients in CE referenced countries.” — Tom Ruggia, CEO and President of Samsara Vision.

ICYMI, last week Samsara Vision announced the first surgery of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®) in a pseudophakic patient. Dr. John Conrath, a leading vitreoretinal and cataract surgeon at Centre Monticelli-Paradis, Marseille, France conducted the surgery.

In CE referenced countries (where the SING IMT® is approved) surgeons participating in the PERSPECTIVE study are evaluating the implantation of the device in late-stage AMD patients who have a previously implanted intraocular lens (IOL) used in cataract surgery.

The inclusion of this population is clinically significant because this subgroup represents a large proportion of individuals affected by late-stage AMD who are not eligible for any other interventions, as Tom explains in the press release. Find it on our website.

10/14/2025

”We’re excited to advance the PERSPECTIVE clinical trial to generate meaningful data to inform a possible label expansion so that we can offer our sight-enhancing device to many more patients in CE referenced countries.” — Tom Ruggia, CEO and President of Samsara Vision.

ICYMI, last week Samsara Vision announced the first surgery of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®) in a pseudophakic patient. Dr. John Conrath, a leading vitreoretinal and cataract surgeon at Centre Monticelli-Paradis, Marseille, France conducted the surgery.

In CE referenced countries (where the SING IMT® is approved) surgeons participating in the PERSPECTIVE study are evaluating the implantation of the device in late-stage AMD patients who have a previously implanted intraocular lens (IOL) used in cataract surgery.

The inclusion of this population is clinically significant because this subgroup represents a large proportion of individuals affected by late-stage AMD who are not eligible for any other interventions, as Tom explains in the press release. Read it here: https://www.samsaravision.com/press-releases/detail/74/samsara-vision-announces-first-pseudophakic-surgery-in-the

10/07/2025

When Samsara Vision’s Rebecca Kammer talks about the SING IMT®️ implant, you can tell just how much this work means to her. Hear why she finds this work so rewarding.

10/06/2025

Samsara Vision is pleased to announce the initiation and the first surgery of the PERSPECTIVE clinical trial to evaluate the efficacy and safety of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®) in pseudophakic patients.

On September 30, 2025, Dr. John Conrath, a leading vitreoretinal and cataract surgeon at Centre Monticelli-Paradis, Marseille, France, conducted the first procedure.

In CE-referenced countries where the SING IMT® is approved for use, surgeons participating in the PERSPECTIVE study are evaluating the implantation of the SING IMT® in late-stage AMD patients who have a previously implanted intraocular lens (IOL) used in cataract surgery.

PERSPECTIVE clinical trial is just one more way that Samsara Vision is helping late-stage AMD patients reconnect to the things in life that they love to see and do.

Read the full press release to learn more about Samsara Vision and PERSPECTIVE: https://www.businesswire.com/news/home/20251006881454/en/Samsara-Vision-Announces-First-Pseudophakic-Surgery-in-the-PERSPECTIVE-Clinical-Trial-to-Evaluate-the-Smaller-Incision-New-Generation-Implantable-Miniature-Telescope-SING-IMT-in-Patients-with-Previous-Cataract-Surgery

09/29/2025

Each Samsara Vision patient comes in with a slightly different set of goals. Rebecca Kammer explains what different patients can expect after the intraocular telescope implant and rehab sessions.

09/17/2025

Where in the world is Samsara Vision? Recently, the team was in Paris to attend Euretina.

Representing the U.S. based contingent, Tom Ruggia and Dr. Rebecca Kammer, joined the EU team at this annual retina event. The team interacted with talented physicians while sharpening progress on technical ideas.

09/10/2025

Samsara Vision welcomes Don Manser to the team as our new Vice President of U.S. Commercial Strategy!

Don brings more than 14 years of experience in Ophthalmology, with a strong focus in Retina. He played a pivotal role in the successful launch and promotion of YUTIQ at EyePoint, and is highly respected across the U.S. Retina community.

Don’s career journey began with 21 years at Xerox before transitioning into the pharmaceutical industry. Since then, Don has excelled in leadership roles across sales, training, and marketing, driving impact in multiple specialties and disease states.

Outside of work, Don enjoys golf, fishing, and collecting rare antiquarian books on military history.

At Samsara Vision, we’re on a mission to restore freedom and vision for the millions of patients living with late-stage AMD. Bringing in leaders like Don is key to making that mission a reality.

Welcome to the team, Don!

07/23/2025

🔦EMPLOYEE SPOTLIGHT: Riley Francis is Samsara Vision’s summer intern, and she is currently fulfilling the role of Chief of Staff.

The Chief of Staff role allows her to contribute across various departments and tackle special projects assigned to her by Samsara Vision’s CEO, Tom Ruggia.

Riley is going into her final year at the University of Michigan, pursuing a degree in Neuroscience and minoring in Biochemistry. She comes to Samsara with practical experience working alongside surgeons, aligning with her goal of attending medical school.

Riley was also a Division 1 Varsity athlete on the Women's Swim team at the University of Michigan. She competed at elite levels, including semi-finaling at the U.S. Olympic Trials, as well as honored Second-Team All-Big Ten Conference.

Go Blue! And go Riley!